ASBPW vs GRWG vs SNDL vs HYFM vs ACB

For growth investors, Aurora Cannabis Inc.

(ACB) is the stronger pick with 27. 0% revenue growth year-over-year, versus -16. 0% for Hydrofarm Holdings Group, Inc. (HYFM). Aurora Cannabis Inc. (ACB) offers the better valuation at 163. 5x trailing P/E, making it the more compelling value choice. Analysts rate SNDL Inc. (SNDL) a "Hold" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Aspire Biopharma Holdings, Inc.

(ASBPW) delivered a total return of -76. 9%, compared to -99. 8% for Hydrofarm Holdings Group, Inc. (HYFM). Over 10 years, the gap is even starker: GRWG returned -75. 7% versus HYFM's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hydrofarm Holdings Group, Inc.

(HYFM) is the lower-risk stock at 0. 73β versus Aspire Biopharma Holdings, Inc. 's 3. 54β — meaning ASBPW is approximately 384% more volatile than HYFM relative to the S&P 500. On balance sheet safety, SNDL Inc. (SNDL) carries a lower debt/equity ratio of 15% versus 76% for Hydrofarm Holdings Group, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Aurora Cannabis Inc.

(ACB) is pulling ahead at 27. 0% versus -16. 0% for Hydrofarm Holdings Group, Inc. (HYFM). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to -381. 5% for Aspire Biopharma Holdings, Inc.. Over a 3-year CAGR, ACB leads at 15. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aurora Cannabis Inc.

(ACB) is the more profitable company, earning 0. 5% net margin versus -16351. 8% for Aspire Biopharma Holdings, Inc. — meaning it keeps 0. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACB leads at 1. 4% versus -10314. 0% for ASBPW. At the gross margin level — before operating expenses — ACB leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hydrofarm Holdings Group, Inc.

(HYFM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73)). Aspire Biopharma Holdings, Inc. (ASBPW) carries a higher beta of 3. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HYFM: -99. 8%, ASBPW: -76. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ASBPW (Healthcare) and GRWG (Consumer Cyclical) and SNDL (Healthcare) and HYFM (Industrials) and ACB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ASBPW is a small-cap quality compounder stock; GRWG is a small-cap quality compounder stock; SNDL is a small-cap quality compounder stock; HYFM is a small-cap quality compounder stock; ACB is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.